Related Experiment Video

Updated: Feb 19, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease

Lisa Argnani1, Alessandro Broccoli1, Pier Luigi Zinzani1

  • 1Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.

Cancer Treatment Reviews
|November 6, 2017
PubMed

Insights

For cutaneous T-cell lymphoma (CTCL) that has relapsed or is refractory, new targeted therapies offer hope. Clinical trials are crucial for advancing treatment options for this rare cancer.

Area of Science:

  • Oncology
  • Dermatology
  • Hematology

Background:

  • Cutaneous T-cell lymphoma (CTCL) presents a poor prognosis in relapsed or refractory cases.
  • Current treatment strategies for advanced CTCL are limited, representing an unmet medical need.

Purpose of the Study:

  • To review emerging data on novel targeted agents for relapsed/refractory CTCL.
  • To highlight current FDA-approved therapies and investigational agents.

Main Methods:

  • Review of clinical trial data for novel targeted agents in CTCL.
  • Summary of approved single-agent therapies: bexarotene, romidepsin, vorinostat.
  • Discussion of investigational agents like brentuximab vedotin and combination strategies.

Main Results:

  • Bexarotene, romidepsin, and vorinostat are FDA-approved single agents for relapsed/refractory CTCL.
  • Brentuximab vedotin shows promise and has orphan designation in Europe.
  • Multiple novel agents and combination therapies are under investigation.

Conclusions:

  • Novel targeted agents are expanding therapeutic options for relapsed/refractory CTCL.
  • Participation in clinical trials is strongly encouraged for patients.
  • Further research and clinical trials are essential to optimize CTCL management.
Keywords:
ARGX-110BortezomibBrentuximab vedotinCopanlisibForodesineGemcitabineHDAC inhibitorsIPH4102IpilimumabMogamulizumabNM-IL-12NivolumabPanobinostatPegylated liposomal doxorubicinPentostatinPralatrexateRomidepsinToll-like receptor agonistsZanolimumabcutaneous T-cell lymphoma

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K